Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC increased its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 50.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 905,209 shares of the company’s stock after acquiring an additional 302,367 shares during the quarter. Fisher Asset Management LLC owned approximately 0.99% of Myriad Genetics worth $12,410,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Atria Investments Inc boosted its position in Myriad Genetics by 5.4% during the third quarter. Atria Investments Inc now owns 11,414 shares of the company’s stock worth $313,000 after acquiring an additional 581 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Myriad Genetics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,285 shares of the company’s stock valued at $87,000 after purchasing an additional 583 shares during the last quarter. Creative Planning boosted its holdings in shares of Myriad Genetics by 9.8% in the 3rd quarter. Creative Planning now owns 9,949 shares of the company’s stock valued at $273,000 after purchasing an additional 892 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Myriad Genetics in the 3rd quarter valued at $32,000. Finally, Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Myriad Genetics by 43.8% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 4,833 shares of the company’s stock valued at $132,000 after purchasing an additional 1,471 shares during the last quarter. Institutional investors and hedge funds own 99.02% of the company’s stock.

Analyst Upgrades and Downgrades

MYGN has been the topic of a number of research analyst reports. UBS Group decreased their price target on shares of Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, February 25th. StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday. Piper Sandler decreased their price target on shares of Myriad Genetics from $24.00 to $14.00 and set a “neutral” rating on the stock in a report on Thursday, January 30th. Leerink Partnrs lowered shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Finally, Bank of America decreased their price target on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a report on Monday. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $22.00.

Myriad Genetics Stock Performance

Myriad Genetics stock opened at $10.39 on Tuesday. Myriad Genetics, Inc. has a 12-month low of $9.76 and a 12-month high of $29.30. The company has a market capitalization of $945.85 million, a price-to-earnings ratio of -7.99 and a beta of 1.88. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The firm’s fifty day moving average price is $13.21 and its 200 day moving average price is $18.79.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The firm had revenue of $210.60 million for the quarter, compared to analysts’ expectations of $210.35 million. During the same period last year, the firm earned ($0.12) EPS. On average, research analysts forecast that Myriad Genetics, Inc. will post -0.3 EPS for the current fiscal year.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.